
Adam Sharp, PhD, BM, MRCP, BSc, discusses preliminary safety and efficacy findings from a phase 1/2 study of gedatolisib plus darolutamide in patients with mCRPC.
In this video, Susan F. Slovin, MD, PhD, discusses considerations that physicians should know when they are beginning to implement immunotherapy in their practice, which are ideas associated with a presentation that she gave at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies. Slovin is a medical oncologist at the Memorial Sloan Kettering Cancer Center in New York City, New York.






